Effect of saikosaponin, a triterpene saponin, on apoptosis in lymphocytes:: association with c-myc, p53, and bcl-2 mRNA

1 The mechanisms involved in the apoptotic effect of saikosaponin-d. a triterpene saponin from Bupleurum falcatum L., were studied in human CEM lymphocytes and compared with those of dexamethasone (3 x 10(-7) M). 2 Saikosaponin-d (10(-8) to 10(-5) M) inhibited the serum-stimulated [H-3]-thymidine incorporation in a concentration-dependent manner. Dexamethasone also inhibited serum-stimulated [H-3]-thymidine incorporation. 3 Cell viability was unaffected by saikosaponin-d until 10(-5)-10(-4) M. Dexamethasone significantly reduced the number of viable cells. 4 Following saikosaponin-d (10(-5)-10(-4) M) treatment. flow cytometry analysis of propidium iodide-stained cells showed a significant increase in the percentage of cells in the apoptotic region. Dexamethasone also significantly increased the percentage of apoptotic cells. The supravital exposure to propidium iodide and annexin V labelling demonstrated that saikosaponin-d (10(-5)-10(-4) M) induced apoptosis as well as necrosis. 5 The apoptotic effect of saikosaponin-d (3 x 10(-6)-10(-4) M) was also demonstrated by TUNEL analysis and DNA laddering. The percentage of apoptotic cells induced by saikosaponin-d (3 x 10(-6)-10(-5) M) was unaffected by the presence of Z-VAD-FMK, indicating that saikosaponin-d-induced apoptosis may not be mediated by caspase activity. However, the percentage of apoptotic cells induced by dexamethasone was significantly reduced by the presence of Z-VAD-FMK. 6 Levels of c-myc, p53, and bcl-2 mRNA were analysed by the reverse transcription-polymerase chain reaction. Levels of c-myc and p53 mRNA were significantly increased, while the level of bcl-2 mRNA was decreased, by saikosaponin-d (10(-5) M) treatment. Dexamethasone did not significantly change the expression of these genes. 7 It is suggested that the apoptotic effect of saikosaponin-d may be partly mediated by increases in c-myc and p53 mRNA levels accompanied by a decrease in bcl-2 mRNA level.